-transparent.png){kind=logo}
Six hundred forty-three children, negative for markers of hepatitis B virus (HBV) infections, were given three X 2-micrograms doses of Merck, Sharp and Dohme (MSD) plasma derived hepatitis B vaccine (H-B-Vax) at monthly intervals. Twelve months after the first dose of vaccine, antibody to hepatitis B surface antigen (anti-HBs) was detected in 89% of children by radioimmunoassay (RIA) and in 83% by enzyme immunoassay (EIA). Seroconversion rates and anti-HBs titres were significantly greater in 1-4-year-olds than in older children (p less than 0.01). Eighteen children with no anti-HBs or other markers of HBV at this time were given 10 micrograms of vaccine and tested one month later. Seventeen developed anti-HBs, 12 at levels consistent with an anamnestic response. Forty-nine HBV-marker-negative children seroconverted for antibody to hepatitis B core antigen (anti-HBc) in the 8-month period before or the 12-month period following vaccination. Forty-six of these children were positive for anti-HBs, and one has been confirmed as a chronic carrier of hepatitis B surface antigen (HBsAg). Three cases of clinical hepatitis B in children have been seen in the community since the vaccination programme began. Two of these were amongst the estimated 5% of children who were not vaccinated. The third was in a vaccinee and occurred 4 1/2 months after the last dose of vaccine.(ABSTRACT TRUNCATED AT 250 WORDS)
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
October 2002,
Infection,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
February 1986,
The New Zealand medical journal,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
August 1995,
The Pediatric infectious disease journal,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
July 2001,
Vaccine,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
October 2010,
Infection,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
November 1988,
Lakartidningen,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
June 1995,
Lancet (London, England),
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
March 1992,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
January 1982,
Nephrologie,
A Milne, and
M Dimitrakakis, and
C Campbell, and
R Lucas, and
G Allwood, and
P Goldwater, and
N Pearce, and
S Krugman
November 1993,
The Pediatric infectious disease journal,
